Angiex in the media

Angiex was featured as one of a select few companies in Labiotech’s article on building successful biotech startups. CEO Paul Jaminet shared insights on the advantages of Cambridge’s biotech ecosystem.

Angiex is featured in Drug Discovery World as a leading North American biotech innovator. CEO Paul Jaminet discusses the critical role of Cambridge’s infrastructure in the company’s early success and its development of TM4SF1-directed ADCs.

Angiex doses the first patient in its Phase 1 trial of a novel antibody-drug conjugate (ADC) therapy targeting blood vessels in tumors, marking a significant milestone in cancer treatment development

Abzena supplies critical materials for Angiex’s AGX101 Phase I trial, supporting the development of a TM4SF1-targeted ADC designed to combat aggressive cancers by focusing on tumor blood vessels.

Angiex doses the first patient in its Phase 1 trial of a novel antibody-drug conjugate (ADC) therapy targeting blood vessels in tumors, marking a significant milestone in cancer treatment development.

Angiex’s Phase I clinical trial for AGX101, a TM4SF1-targeted ADC, moves forward with critical support from Abzena, a CDMO that provides essential manufacturing expertise for cancer therapy development.

Abzena provides clinical trial materials for Angiex’s Phase I cancer study, supporting the development of AGX101, an innovative TM4SF1-targeted antibody-drug conjugate aimed at treating aggressive cancers.

Angiex launches a Phase I clinical trial of AGX101, its novel TM4SF1-targeted ADC therapy, marking a pivotal step in the development of new treatments for aggressive forms of cancer.

Abzena provides clinical trial materials for Angiex’s Phase 1 study of AGX101, a first-in-class TM4SF1-targeted ADC designed to treat aggressive tumors by focusing on blood vessel disruption.

Abzena collaborates with Angiex to support its Phase I trial for AGX101, a TM4SF1-targeted ADC aimed at treating solid tumors by targeting tumor blood vessels.

Abzena provides critical clinical trial materials for Angiex’s Phase I study of AGX101, a TM4SF1-directed ADC designed to target blood vessels in tumors, marking progress in cancer therapy development.

Abzena supports Angiex’s Phase I study of AGX101, a novel TM4SF1-directed ADC, by supplying the necessary clinical trial materials for this first-in-class cancer therapy targeting tumor blood vessels.

Angiex kicks off its Phase 1 clinical trial for AGX101, a cutting-edge TM4SF1-targeted ADC designed to treat aggressive cancers by targeting tumor blood vessels.

Angiex’s AGX101, a novel TM4SF1-directed antibody-drug conjugate (ADC) targeting solid tumors, enters Phase I clinical trials, marking a new phase in precision cancer treatment.

Abzena provides clinical trial materials for Angiex’s Phase I study of AGX101, a novel TM4SF1-directed ADC, supporting the development of targeted therapies against aggressive cancers.

As noted by ADC Review, AGX101 has shown promising preclinical results and could represent a breakthrough in the fight against cancers that rely on angiogenesis. Angiex partnered with Abzena for the manufacturing of the clinical trial material, further accelerating AGX101’s path to market.

Angiex’s dosing of the first patient in its AGX101 Phase 1 trial was covered by Clinical Trials Arena, a key publication from GlobalData, and known for its influential insights on clinical trial advancements.

Angiex was featured in a NASA article on the International Space Station’s role in advancing healthcare innovations on Earth. The piece highlights Angiex’s cancer research using microgravity to test its TM4SF1-targeted therapy.

BusinessWeek featured Angiex in a story on the unique advantages of conducting pharmaceutical research on the International Space Station (ISS). CSO Shou-Ching Jaminet shared insights into Angiex’s pioneering cancer research in microgravity.